GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
19.05
+1.05 (5.83%)
May 15, 2025, 3:59 PM EDT
GSK plc Revenue
GSK plc had revenue of 7.52B GBP in the quarter ending March 31, 2025, with 2.08% growth. This brings the company's revenue in the last twelve months to 31.53B, up 2.57% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.53B GBP
Revenue Growth
+2.57%
P/S Ratio
1.80
Revenue / Employee
459.41K GBP
Employees
68,629
Market Cap
73.48B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
GSK plc News
- 1 day ago - iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating - Seeking Alpha
- 1 day ago - GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion - Benzinga
- 1 day ago - GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B - Seeking Alpha
- 1 day ago - GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - WSJ
- 1 day ago - GSK to buy efimosfermin for up to $2 billion - Reuters
- 1 day ago - GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) - Business Wire
- 1 day ago - FTSE 100 Live 14 May: GSK unveils $2bn acquisition, Imperial Brands posts results - Evening Standard
- 1 day ago - GSK Pharma share price jumps 5% as Q4 EBITDA rises 29.5% YoY to Rs 333.2 crore - Business Upturn